Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P53 and its molecular basis to chemoresistance in breast cancer.

Expert opinion on therapeutic targets - 1 Mar 2012

Knappskog Stian, Lønning Per Eystein

Abstract excerpt

INTRODUCTION: TP53 mutations have been associated with resistance to anthracyclines and mitomycin in breast cancer. This review examines the potential roles of different components in the p53 cascade with respect to drug resistance. AREAS COVERED: Literature was searched using the ISI Web and Pub...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Mutation

Share to Protein Serine-Threonine Kinases

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 22313396
DOI: 10.1517/14728222.2011.640322

Genes

ATM
ATR
BRCA1
CHEK2
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22313396-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P53 and its molecular basis to chemoresistance in breast cancer.PMID 22313396Read ↗

p53 in breast cancer: mutation and countermeasures.Semantic proximity Read ↗

The p53 pathway in breast cancer.Semantic proximity Read ↗

TP53 status and response to chemotherapy in breast cancer.Semantic proximity Read ↗

Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic StrategiesSemantic proximity Read ↗

Dysregulation of P53 in breast cancer: Causative factors and treatment strategies.Semantic proximity Read ↗

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.Semantic proximity Read ↗

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.Semantic proximity Read ↗

p53 in breast cancer subtypes and new insights into response to chemotherapy.Semantic proximity Read ↗

Role of p53 mutations in the radiosensitivity status of tumor cells.Semantic proximity Read ↗

TP53 status and response to treatment in breast cancers.Semantic proximity Read ↗

Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.Semantic proximity Read ↗

A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.